The first active agent from our platform technology, VERIOX™, has undergone significant pre-clinical efficacy and safety testing.  Using VERIOX™ as our first-generation active agent, we intend VERIOX™ to target areas that are underserved in terms of new technology and clinical outcomes in the orthopedics, wound and surgical spaces.

We are pursuing three VERIOX™-containing medical products for uses in the wound, orthopedic and dermatology markets.  Simultaneously with our product development efforts, we are beginning to develop the product manufacturing and commercialization infrastructure to bring our technology to market and to partner with other companies to bring value to their product lines.